Authors: Katsuhito Hori Norihiro Kobayashi Hitoshi Atsumi Akira Nagayama Masako Kondoh Ichiro Noge Midori Kimura Hiroaki Utsugi Tsuyoshi Iwasaki Masaki Nakamura Tomomi Kimura
Publish Date: 2013/11/26
Volume: 22, Issue: 4, Pages: 969-977
Abstract
Prophylaxis of chemotherapy CTinduced nausea and vomiting CINV is important for patient’s quality of life and adherence to CT Neurokinin receptor antagonist NK1 antagonist was marketed in Japan in December 2009 and the first guideline for antiemetics for CINV was released in May 2010 from Japan Society of Clinical Oncology JSCO We assessed changes in compliance with the JSCO guideline during the first 18 months from the launch of NK1 antagonist in JapanIn total 81739 CTs for 9978 patients were analyzed Prescription of oral NK1 antagonist was started in 31/39 hospitals during the study period The compliance in acute phase for high emetic risk HER CTs gradually improved up to 393 whereas it reached only to 10–15 in delayed phase The extra use of antiemetics decreased inversely to the increased compliance Better compliance for HER CTs was associated with opioid use younger age second or later cycles and CT regimens Compliance in acute phase was better in inpatient whereas that in delayed phase was better in outpatients
Keywords: